Published on 06/12/2025
Totality of evidence approach to indication extrapolation for biosimilars
The biosimilars market is rapidly evolving, and understanding the regulatory landscape surrounding biosimilar development, particularly regarding pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity, is vital for regulatory professionals. This regulatory explainer manual will provide a comprehensive overview of the totality of evidence approach to indication extrapolation for biosimilars, focusing on the expectations of regulatory agencies in the US, UK, and EU, including the FDA, EMA, and MHRA, as well as the interaction with other regulatory areas such as Chemistry, Manufacturing and Controls (CMC), Clinical, Pharmacovigilance (PV), Quality Assurance (QA), and Commercial sectors.
Context
Biosimilars are biologic products that are highly similar to an already approved biological reference product. The development of biosimilars requires a robust understanding of the reference product’s properties and a detailed regulatory pathway to demonstrate clinical comparability, immunogenicity, and safety across different indications. The totality of evidence framework allows for the assessment of biosimilars in multiple indications based on data gathered primarily from one or a few indications.
Legal/Regulatory Basis
The regulation of biosimilars varies across regions, but central to their approval is the demonstration of comparability to the reference biologic. In the
Documentation
Documentation is critical in biosimilar development, particularly in relation to PK/PD studies, clinical immunogenicity assessments, and extrapolation of indications. Key documentation typically includes:
- Quality Data: Comprehensive information on the product’s chemistry, manufacturing, and controls, aligning with ICH Q6B guidelines.
- Preclinical Data: In vitro and in vivo studies supporting PK/PD and immunogenicity.
- Clinical Data: Results from clinical comparability studies and justification for extrapolation of indications.
- Risk Management Plans: Detailed plans addressing potential immunogenicity risks.
Review/Approval Flow
The review process for biosimilars involves a series of steps:
- Pre-IND Meetings: Engaging FDA or relevant authorities early in the development process can aid in planning clinical studies.
- IND Submission: A comprehensive IND application must include all required preclinical data, along with a clear rationale for the proposed clinical studies.
- Clinical Phase: Execution of PK/PD and clinical comparability studies.
- BLA Submission (US) / MA Application (EU): Submission of all required data and documentation demonstrating safety and efficacy.
- Post-market Surveillance: Continuous monitoring for safety and immunogenicity post-approval, as outlined in the Risk Management Plan.
Common Deficiencies
Agencies frequently cite several deficiencies regarding biosimilar applications. Common issues include:
- Insufficient PK/PD data: Failure to adequately demonstrate pharmacokinetic and pharmacodynamic comparability can lead to additional requirements.
- Lack of justification for indication extrapolation: Agencies require clear scientific justification based on the totality of evidence. Deficiencies may arise if the rationale is not thoroughly articulated.
- Immunogenicity concerns: Inadequate data on the immunogenicity risks and management strategies may be a point of contention.
Decision Points
When strategizing for biosimilar development, several key decision points emerge:
Filing as a Variation vs. New Application
Determining whether to file a variation or a new application depends on the extent of changes made to the reference product or the biosimilar itself. A variation may be appropriate for minor changes that don’t alter the product’s fundamental characteristics, while a new application may be warranted for significant modifications. Key factors guiding this decision include:
- Type and extent of changes to the production process
- Existing data supporting change
- Impact on safety, efficacy, and quality profile
Justifying Bridging Data
Bridging data is essential, particularly for extrapolating indications. When different populations or indications are involved, bridging data helps establish the biosimilar’s similarity to the reference product in terms of safety and efficacy. Strategies may include:
- Conducting robust comparative studies in the reference population and extrapolating findings to other populations.
- Using PK/PD modeling to demonstrate consistency across indications.
Conclusion
Understanding the totality of evidence approach to indication extrapolation in biosimilar development is critical for regulatory affairs professionals. Extensive knowledge of regulatory expectations, intricate documentation practices, and proactive engagement with regulatory bodies greatly minimizes the risk of deficiencies and provides a structured pathway towards approval. By ensuring thorough justification for clinical comparability studies and addressing immunogenicity risks, developers can navigate the complexities inherent in biosimilar regulation.
Professionals involved in biosimilar development are encouraged to keep abreast of evolving guidelines and interpretations from regulatory agencies to maintain compliance and optimize approval strategies.